.Pharmacolibrary.Drugs.ATC.N.N06DA02

Information

Donepezil is an acetylcholinesterase inhibitor used to treat symptoms of Alzheimer's disease by increasing levels of acetylcholine in the brain. It is approved and widely used today as a first-line medication for mild to moderate dementia of the Alzheimer's type.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration of 5 mg donepezil.

References

1. Choi, HY, et al., & Lim, HS (2015). Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers. European journal of clinical pharmacology 71(8) 967–977. DOI:10.1007/s00228-015-1875-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26014587

2. Khwarg, J, et al., & Chung, JY (2024). Population Pharmacokinetic Modeling and Simulation for Dose Optimization of GB-5001, a Long-Acting Intramuscular Injection of Donepezil, in Healthy Participants. Neurology and therapy 13(5) 1453–1466. DOI:10.1007/s40120-024-00643-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39126603

3. Jung, W, et al., & Yun, HY (2022). Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation. Pharmaceutics 14(2) –. DOI:10.3390/pharmaceutics14020244 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35213976

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)